Navigation Links
World TB Day Senate Briefing
Date:3/23/2010

WASHINGTON, March 23 /PRNewswire-USNewswire/ --

What:

A Senate briefing, Bringing Established Methods to Scale: New Perspectives in the Changing World of TB, to discuss TB and drug-resistant TB, including multidrug-resistant TB (MDR-TB) and extensively-drug resistant (XDR-TB), the impact on global health and the current state of surveillance, diagnosis and treatment around the world.

Who:

Co-hosts include the Global Health Council, American Thoracic Society, Stop TB Partnership and The Lilly MDR-TB Partnership.

Speakers:

  • Dr. Ernesto Jaramillo, Team Leader for MDR-TB, Stop TB Department, World Health Organization
  • Dr. Rachel Nugent, Center for Global Development - MDR-TB and its relation to global health
  • Dr. Celine Gounder, Consortium to Respond Effectively to the AIDS/TB Epidemic (CREATE) - The combined TB and HIV epidemic and the effects of community-based research

Moderator: Smita Baruah, Global Health Council

When:

World TB Day, Wednesday, March 24, 2010, 10:00 a.m.11:30 a.m. ET

Where:

Hart Senate Office Building, Room SH-902

Washington, DC

Why:

This year's World TB Day marks the midway point for the Global Plan to Stop TB. The plan's goals are to expand equitable access for all to quality TB diagnosis and treatment; to treat 50 million people; to save 14 million lives; to introduce in 2010 the first new TB drug in 40 years; to detect active TB through diagnostic tests at the point of care allowing rapid, sensitive and inexpensive detection by 2010; and to have a new, safe, effective and affordable vaccine by 2015.

Current TB statistics:

  • There were 9.4 million new TB cases in 2008, including 1.4 million cases among people living with HIV(1)
  • 1.8 million people died from TB in 2008, including 500,000 people with HIV - equal to 4,500 deaths a day(1)
  • TB is a leading killer of people with HIV(1)
  • Today's TB drugs are more than 40 years old and must be taken for at least six to nine months for drug-susceptible tuberculosis(2)
  • MDR-TB is a form of TB that is difficult and expensive to treat and fails to respond to standard first-line drugs. (1)  There were an estimated 500,000 new MDR-TB cases in 2007. Just over 1% of cases were receiving treatment in 2008 known to be based on WHO's recommended standards(1)
  • XDR-TB, which occurs when resistance to second-line drugs develops on top of MDR-TB, been found in 57 countries to date(1)

For more information, please go to http://www.globalhealth.org/news/article/12157

(1) "2009 Update Tuberculosis Facts;" http://www.who.int/tb/publications/2009/tbfactsheet_2009update_one_page.pdf  World Health Organization, Stop TB Partnership. 18 Mar. 2010

(2) "Mission and History;" http://www.tballiance.org/about/mission.php. TB Alliance. 18 Mar. 2010

SOURCE The Lilly MDR-TB Partnership

Back to top

RELATED LINKS
http://www.globalhealth.org/news/article/12157

'/>"/>

SOURCE The Lilly MDR-TB Partnership
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Georgia Reproductive Specialists Participates in Largest-Ever In Vitro Fertilization Clinical Trial in the World
2. Aspirin Named 8th World Wonder by Majority of Americans
3. Poniard Pharmaceuticals to Present Updated Results of Picoplatin Phase 2 Small Cell Lung Cancer Trial at 12th World Conference on Lung Cancer
4. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
5. A Worldwide Phase III Clinical Trial Seeks U.S. Patients to Explore Investigational Drug Phenoxodiol
6. New Study Presented at WorldSleep 2007 Demonstrates Ramelteon Has Sustained Efficacy Over Six Months in Adults With Chronic Insomnia
7. Genasense(R) Data in Melanoma to be Presented in Opening Session at First Worldwide Melanoma Center Meeting of the European Association of Dermato-Oncology
8. WorldHeart Announces Further Milestone in Miniaturized Assist Pump Development
9. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
10. Pivotal Ustekinumab (CNTO 1275) Phase 3 Data to Debut at World Congress of Dermatology Meeting
11. Video: The Arizona Heart Institute Announces the Largest Worldwide Experience with Endoluminal Grafting to Treat Thoracic Aortic Aneurysms and Related Pathologies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2017)... , May 4, 2017  Fortuna Fix Inc. (" Fortuna ... be the first to eliminate the need for embryonic and ... to treat neurodegenerative diseases. Fortuna announced ... Professor Michael Fehlings , MD, PhD; Father Kevin ... MD, MPH; and Professor James Giordano , PhD. ...
(Date:5/4/2017)... 2017  DarioHealth Corp. (NASDAQ: DRIO), a leading global ... solutions, today announced that it is teaming up with ... Limited to lower diabetes healthcare costs in ... which is available throughout all provinces and territories in ... eligible for additional savings when shopping for Dario supplies ...
(Date:5/3/2017)... ROCKVILLE, Md. , May 3, 2017 /PRNewswire/ ... revenue growth of nine percent next year and ... solid organ and hematopoietic stem cell (HSCT) or ... and donor. Molecular testing technologies are well-suited for this ... healthcare-only market research publisher Kalorama Information. The various ...
Breaking Medicine Technology:
(Date:5/26/2017)... ... ... to the Cross”: the personal journey of Bob Massey and his faith in the Lord. ... and Margaret Massey. Bob Massey is small in stature but big in character. ... love for others is apparent in all of his life decisions. , “I’m in ...
(Date:5/24/2017)... ... May 24, 2017 , ... Last month, representatives ... hospital employees, and town officials to celebrate the grand opening of the 87,000 ... Rendina as part of its ongoing relationship with RWJBarnabas Health, New Jersey’s largest ...
(Date:5/24/2017)... , ... May 24, 2017 , ... ... implants in Bayside, NY, who have now spent 10 years as clinical instructors ... York University (NYU) College of Dentistry. Through the program, private practitioners receive cutting-edge ...
(Date:5/24/2017)... Las Vegas, NV (PRWEB) , ... May 24, ... ... Las Vegas, NV, recently completed Course II of the HP3 (High-Performance Periodontal Practice) ... commits himself to learning the latest advancements in his field by attending numerous ...
(Date:5/24/2017)... Massapequa Park, NY (PRWEB) , ... May 24, ... ... today announced the practice is offering holistic pediatric dentistry options for its patients ... the context of the patient’s entire physical well being, and is one of ...
Breaking Medicine News(10 mins):